# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

> **NCT05262023** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Denali Therapeutics Inc.** · enrollment: 85 (actual)

## Conditions studied

- Frontotemporal Dementia

## Interventions

- **DRUG:** DNL593
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05262023
- **Lead sponsor:** Denali Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2026-12
- **Final completion:** 2028-11
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262023, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05262023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*